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Recently watching a rerun of the 2016 Olympics gymnastics finals, I could not help marveling at the way the joints of the athletes could withstand so many gravity-defying leaps, twists, and landings. These feats are possible because the ends of our bones are covered by articular cartilage, a smooth tissue that allows fluid, pain-free movement. This tissue is made by specialized cells secreting proteins that trap water and form an extracellular matrix which cushions joints.

When articular cartilage wears away, for example in degenerative diseases such as osteoarthritis, movements become painful and quality of life drops severely. Yet, these conditions are increasingly common -- in the United States alone, it is predicted that more than 78 million people could be affected by 2040 ([@bib4]).

Cartilage is not connected to the nervous system or to blood and lymphatic vessels, which means the tissue heals poorly when damaged. Most therapies for osteoarthritis therefore work by preserving the remaining cartilage or preventing further loss. Once the cartilage is lost, few interventions exist: surgeons can carefully damage the bone to promote the creation of new tissue, they can graft bone and cartilage obtained from a donor, or they can completely replace the joints with artificial ones ([@bib10]; [@bib11]; [@bib2]; [@bib7]). However, these interventions may not be durable, and they are limited by factors such as the availability of donor tissue and the age or health condition of the patient.

Another, lab-based approach is to harvest mesenchymal stem cells or chondroprogenitor cells from patients, and then \'coax\' these to create cartilage that can be implanted in the individual ([@bib7]). However, one challenge associated with this method is the stability of the resulting cartilage: over time, it can change into bone, reducing the function of the repaired joint.

Long non-coding RNAs are molecules that regulate an array of genetic events in the cell, and it was reported recently that these sequences are essential to keep cartilage stable: for instance, several long non-coding RNAs are activated in mesenchymal stem cells that produce cartilage ([@bib1]; [@bib5]). Now in eLife, Farshid Guilak and colleagues -- including Nguyen Hyunh as first author -- report having identified a long non-coding RNA called *GRASLND* which encourages mesenchymal stem cells to produce molecules that form cartilage ([@bib6]).

First, the team (which is based at Washington University in St. Louis, the St. Louis Shriners Hospital, Duke University and Vanderbilt University) designed RNA molecules that were used to deactivate *GRASLND* in mesenchymal stem cells. As a result, the production of cartilage decreased and these cells started to show a molecular profile associated with bone formation. These results demonstrate that, in these cells, *GRASLND* is required to maintain a cartilage-forming program ([Figure 1](#fig1){ref-type="fig"}).

![*GRASLND* helps mesenchymal stem cells to create cartilage by suppressing IFN-signaling.\
(**A**) Exposing mesenchymal stem cells (MSCs) to the growth factor TGFβ3 activates the expression of the *Sox9* gene, which triggers the production of a long non-coding RNA called *GRASLND.* (**B**) *GRASLND* binds to the kinase EIF2AK2 (blue), which blocks the inhibitory phosphorylation of the protein EIF2A (green). This, in turn, promotes the expression of \'prochondrogenic factors\' that encourage the production of molecules, such as proteoglycans, which form cartilage; the cell is said to have a \'chondrogenic\' phenotype. (**C**) When *GRASLND* is depleted from mesenchymal stem cells, the kinase EIF2AK2 probably phosphorylates EIF2A (represented here by the '-P\*'). This activates the Type II IFN-γ response, which ultimately leads to a reduction in proteoglycan expression and a loss of the chondrogenic phenotype. *GRASLND*: glycosaminoglycan regulatory associated long non-coding RNA; EIF2A: eukaryotic translation initiation factor two alpha; EIF2AK2: EIF2A kinase; TGFβ3: transforming growth factor beta 3. Figure created using BioRender ([BioRender.com](http://Biorender.com)).](elife-57239-fig1){#fig1}

Further experiments showed that *GRASLND* interacts with EIF2AK2, a kinase that normally inhibits a protein known as EIF2A, which triggers a molecular cascade called the type II IFN-γ signaling pathway ([@bib9]; [@bib8]). This pathway is essential for the immune system, but some of its elements, such as a cytokine called IFN-γ, also help to stimulate bone formation ([@bib3]).

When *GRASLND* binds EIF2AK2, it probably stops this kinase from acting on EIF2A; this suppresses IFN activity while allowing the genes that promote the production of cartilage to be expressed ([Figure 1B](#fig1){ref-type="fig"}). On the other hand, Hyunh et al. find that removing *GRASLND* is associated with an increase in the expression of genes under the control of IFN-γ ([Figure 1C](#fig1){ref-type="fig"}). As IFN-γ promotes bone formation, these findings explain why depleting mesenchymal stem cells of *GRASLND* leads to more bone production.

Finally, Hyunh et al. used data mining to show that, in diseased cartilage, genes regulated by IFN are expressed more abundantly. This suggests that IFN-signaling may be directly responsible for the production of the abnormal, bony nodules that are often present in osteoarthritic cartilage.

Overall, these results indicate that --- at least in vitro --- *GRASLND* is an important modulator of type II IFN-γ signaling that is necessary for cartilage differentiation. They also highlight that this pathway may be involved in diseases of the cartilage. If so, the interaction between *GRASLND* and EIF2AK2 could be an important pharmacological target. Exploring this possibility will first require comparing the expression of *GRASLND* in healthy and diseased cartilage.

*GRASLND* has only been found in primates, but related long non-coding RNAs could be identified in other species by spotting the motifs that *GRASLND* needs to interact with EIF2AK2. In turn, this knowledge could pave the way for better animal models to study how this class of long non-coding RNAs is involved in degenerative joint diseases.
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